ME02492B - Lapatanib za lečenje kancera - Google Patents
Lapatanib za lečenje kanceraInfo
- Publication number
- ME02492B ME02492B MEP-2016-168A MEP16816A ME02492B ME 02492 B ME02492 B ME 02492B ME P16816 A MEP16816 A ME P16816A ME 02492 B ME02492 B ME 02492B
- Authority
- ME
- Montenegro
- Prior art keywords
- hla
- lapatinib
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
Claims (15)
1.Lapatinib, ili njegova farmaceutski prihvatljiva so ili farmaceutska kompozicija, za upotrebu u lečenju kancera kod čoveka, naznačen time, što je za pomenutog ispitanika utvrđeno da nije nosilac jednog ili više alelnih polimorfizama izabranih iz grupe koju čine: HLA-DQA1*0201, HLA-DQB1*0202, i/ili HLA-DRB1*0701.
2.Lapatinib, ili njegova farmaceutski prihvatljiva so ili farmaceutska kompozicija, za upotrebu u lečenju kancera kod čoveka prema patentnom zahtevu 1, naznačen time što je za pomenutog ispitanika utvrđeno da nije nosilac najmanje dva polimorfizma izabrana iz grupe koju čine: HLA-DRB1*0701, HLA-DQA1*0201, i/ili HLA-DQB1*0202.
3.Lapatinib, ili njegova farmaceutski prihvatljiva so ili farmaceutska kompozicija, za upotrebu u lečenju kancera kod čoveka prema patentnom zahtevu 1 ili patentnom zahtevu 2, naznačen time, što se pomenuti lapatinib ili njegova farmaceutski prihvatljiva so ili farmaceutska kompozicija, primenjuje zajedno sa najmanje još jednim antikancerskim agensom.
4.Lapatinib, ili njegova farmaceutski prihvatljiva so ili farmaceutska kompozicija, za upotrebu u lečenju kancera kod čoveka prema patentnom zahtevu 3, naznačen time, što je pomenuti, najmanje jedan, dodatni antikancerski agens izabran iz grupe koju čine: trastuzumab, kapecitabin, paklitaksel, karboplatin, pazopanib i letrozol.
5.Lapatinib, ili njegova farmaceutski prihvatljiva so ili farmaceutska kompozicija, za primenu kod tretirane populacije humanih ispitanika obolelih od kancera, naznačen time, što je pomenuta tretirana populacija izabrana iz početne populacije humanih ispitanika obolelih od kancera i što ima smanjeni procenat ispitanika koji su nosioci polimorfnog HLA alela izabranog iz grupe koju čine: HLA-DQA1*0201, HLA-DQB1*0202 i HLA-DRB1*0701 u poređenju sa početnom populacijom.
6.Lapatinib, ili njegova farmaceutski prihvatljiva so ili farmaceutska kompozicija, za upotrebu u lečenju čoveka obolelog od kancera prema bilo kojem od patentnih zahteva od 1 do 5, naznačen time što je za pomenutog ispitanika takođe utvrđeno da nije nosilac polimorfizama i/ili genotipova rs12153855 i/ili rs17207923 na TNXB genu.
7.Postupak ispitivanja (skrininga) humanog ispitanika obolelog od kancera kao pomoć u predviđanju pojave hepatotoksičnosti povezane sa lapatinibom ili njegovom farmaceutski prihvatljivom soli ili farmaceutskom kompozicijom, koji obuhvata određivanje da li ispitanik ima HLA genotip izabran iz grupe koju čine: HLA-DQA1*0201, HLA-DQB1*0202 i HLA-DRB1*0701, naznačen time što prisustvo takvog HLA genotipa ukazuje na povišen rizik od hepatotoksičnosti povezane sa lapatinibom ili njegovom farmaceutski prihvatljivom soli ili farmaceutskom kompozicijom kod pomenutog humanog ispitanika, u poređenju sa rizikom očekivanim kod opšte populacije.
8.Postupak prema patentnom zahtevu 7 dalje obuhvata utvrđivanje postojanja međusobne povezanosti otkrivanja HLA-DQA1*0201, HLA-DQB1*0202 i/ili HLA-DRB1*0701 alela i povišenog rizika od pojave hepatotoksičnosti povezane sa lapatinibom ili njegovom farmaceutski prihvatljivom soli ili farmaceutskom kompozicijom.
9.Postupak prema patentnom zahtevu 7 ili prema patentnom zahtevu 8, dalje obuhvata određivanje da li je pomenuti ispitanik nosilac genotipa HLA-B*4403, i/ili rs12153855 i/ili rs17207923 na TNXB genu.
10.Postupak prema bilo kojem od patentnih zahteva od 7 do 9 dalje obuhvata određivanje da li je pomenuti ispitanik DQ2.2. seropozitivan.
11.Postupak identifikacije humanog ispitanika obolelog od kancera kod koga postoji povišeni rizik od hepatotoksičnosti povezane sa terapijskim režimom primene lapatiniba, ili njegove farmaceutski prihvatljive soli ili farmaceutske kompozicije, obuhvata: a.izvođenje tehnike genotipizacije na biološkom uzorku poreklom od pomenutog ispitanika u cilju određivanja da li HLA genotip humanog ispitanika uključuje alel izabran iz grupe koju čine: HLA-DQA1*0201, HLA-DQB1*0202 ili HLA-DRB1*0701; b.detektovanje HLA-DQA1*0201, HLA-DQB1*0202 i/ili HLA-DRB1*0701; i c.utvrđivanje postojanja međusobne povezanosti otkrivanja HLA-DQA1*0201, HLA-DQB1*0202 i/ili HLA-DRB1*0701 alela i povećanog rizika od pojave hepatotoksičnosti povezane sa terapijskim režimom primene lapatiniba, ili njegove farmaceutski prihvatljive soli ili farmaceutske kompozicije, u poređenju sa rizikom u slučaju da nijedan od HLA-DQA1*0201, HLA-DQB1*0202 i/ili HLA-DRB1*0701 alela nije otkriven.
12.Postupak prema patentnom zahtevu 11 naznačen time što je pomenuti ispitanik nosilac oba, i HLA-DQA1*0201 i HLA-DQB1*0202 polimorfizma.
13. Postupak prema patentnom zahtevu 11 ili patentnom zahtevu 12, naznačen time, što dalje obuhvata izvođenje tehnike genotipizacije na biološkom uzorku poreklom od pomenutog ispitanika u cilju određivanja da li pomenuti ispitanik ima genotipove rs12153855 i/ili rs17207923 na TNXB genu i utvrđivanje postojanja međusobne povezanosti otkrivanja genotipova rs12153855 i/ili rs17207923 na TNXB genu i povišenog rizika od pojave hepatotoksičnosti povezane sa lapatinibom ili njegovom farmaceutski prihvatljivom soli ili farmaceutskom kompozicijom, u poređenju sa rizikom u slučaju da nijedan od genotipova rs12153855 i/ili rs17207923 na TNXB genu nije otkriven.
14.Lapatinib, ili njegova farmaceutski prihvatljiva so ili farmaceutska kompozicija, za upotrebu u lečenju kancera kod čoveka prema bilo kojem od patentnih zahteva od 1 do 6, ili postupak prema bilo kojem od patentnih zahteva od 11 do 13, naznačen time, što je utvrđeno da je pomenuti ispitanik DQ2.2. seropozitivan.
15. Lapatinib, ili njegova farmaceutski prihvatljiva so ili farmaceutska kompozicija, za upotrebu u lečenju čoveka obolelog od kancera prema bilo kojem od patentnih zahteva od 1 do 6 ili 14, ili postupak prema bilo kojem od patentnih zahteva od 7 do 13, naznačen time, što pomenuti kancer predstavlja kancer dojke.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23594709P | 2009-08-21 | 2009-08-21 | |
| US30756910P | 2010-02-24 | 2010-02-24 | |
| EP10810654.3A EP2467140B1 (en) | 2009-08-21 | 2010-08-20 | Lapatinib for treating cancer |
| PCT/US2010/046142 WO2011022633A2 (en) | 2009-08-21 | 2010-08-20 | Method of threating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02492B true ME02492B (me) | 2017-02-20 |
Family
ID=43607603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-168A ME02492B (me) | 2009-08-21 | 2010-08-20 | Lapatanib za lečenje kancera |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20120156200A1 (me) |
| EP (1) | EP2467140B1 (me) |
| JP (1) | JP5876827B2 (me) |
| KR (1) | KR101781658B1 (me) |
| CN (1) | CN102770140B (me) |
| AU (2) | AU2010284092A1 (me) |
| BR (1) | BR112012003653A2 (me) |
| CA (2) | CA2771699C (me) |
| CY (1) | CY1118486T1 (me) |
| DK (1) | DK2467140T3 (me) |
| EA (1) | EA027959B1 (me) |
| ES (1) | ES2589377T3 (me) |
| HR (1) | HRP20161110T1 (me) |
| HU (1) | HUE029098T2 (me) |
| IL (1) | IL218230B (me) |
| LT (1) | LT2467140T (me) |
| ME (1) | ME02492B (me) |
| MX (1) | MX367580B (me) |
| PL (1) | PL2467140T3 (me) |
| PT (1) | PT2467140T (me) |
| RS (1) | RS55074B1 (me) |
| SG (2) | SG10201405039VA (me) |
| SI (1) | SI2467140T1 (me) |
| SM (1) | SMT201600296B (me) |
| WO (1) | WO2011022633A2 (me) |
| ZA (1) | ZA201201110B (me) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8916574B2 (en) | 2009-09-28 | 2014-12-23 | Qilu Pharmaceutical Co., Ltd. | 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors |
| KR20140117644A (ko) * | 2012-01-31 | 2014-10-07 | 스미스클라인 비이참 (코르크) 리미티드 | 암을 치료하는 방법 |
| GB201403820D0 (en) * | 2014-03-04 | 2014-04-16 | Isis Innovation | Assay |
| CN104293958B (zh) * | 2014-10-16 | 2016-09-21 | 卫生部北京医院 | 一种预测强直性脊柱炎易感性的试剂盒和方法 |
| RU2761249C2 (ru) | 2016-12-14 | 2021-12-06 | Мерк Шарп энд Доум Корп. | Человеческие генетические маркеры, ассоциированные с ответом на средства для лечения, которые целенаправленно воздействуют на токсин b clostridium difficile |
| JP2025142656A (ja) * | 2024-03-18 | 2025-10-01 | 学校法人昭和大学 | アベマシクリブまたはその薬学的に許容可能な塩による肝障害発現リスクの検査方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4582788A (en) | 1982-01-22 | 1986-04-15 | Cetus Corporation | HLA typing method and cDNA probes used therein |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5871918A (en) | 1996-06-20 | 1999-02-16 | The University Of North Carolina At Chapel Hill | Electrochemical detection of nucleic acid hybridization |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| JP2000508912A (ja) | 1996-04-19 | 2000-07-18 | スペクトラ バイオメディカル，インコーポレイテッド | 多型形態と複数の表現型との相関付け |
| JP4386967B2 (ja) | 1996-07-13 | 2009-12-16 | グラクソ、グループ、リミテッド | プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物 |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| IL153111A0 (en) | 2000-06-30 | 2003-06-24 | Glaxo Group Ltd | Quinazoline ditosylate salt compounds |
| US20070281041A1 (en) * | 2004-03-02 | 2007-12-06 | Introgen Therapeutics, Inc. | Compositions and Methods Involving MDA-7 for the Treatment of Cancer |
| US7794960B2 (en) * | 2004-06-04 | 2010-09-14 | Glaxosmithkline Llc | Predictive biomarkers in cancer therapy |
| JP2007117085A (ja) | 2005-09-28 | 2007-05-17 | Genodive Pharma Kk | 塩酸チクロピジンの副作用である肝臓障害の発生危険率の検査方法 |
| WO2007099852A1 (ja) | 2006-02-23 | 2007-09-07 | National University Corporation Kanazawa University | 固形癌のチロシンキナーゼ阻害剤に対する感受性を検査する方法及び検査キット |
| WO2008070448A2 (en) * | 2006-11-22 | 2008-06-12 | Board Of Regents, The University Of Texas System | Cancer-specific promoters |
| US20080131887A1 (en) * | 2006-11-30 | 2008-06-05 | Stephan Dietrich A | Genetic Analysis Systems and Methods |
| WO2008112903A2 (en) * | 2007-03-13 | 2008-09-18 | The Children's Hospital Of Philadelphia | Genetic alterations on chromosome 16 and methods of use thereof for the diagnosis and treatment of type 1 diabetes |
-
2010
- 2010-08-20 SI SI201031257A patent/SI2467140T1/sl unknown
- 2010-08-20 HR HRP20161110TT patent/HRP20161110T1/hr unknown
- 2010-08-20 SG SG10201405039VA patent/SG10201405039VA/en unknown
- 2010-08-20 ME MEP-2016-168A patent/ME02492B/me unknown
- 2010-08-20 SG SG2012010658A patent/SG178439A1/en unknown
- 2010-08-20 ES ES10810654.3T patent/ES2589377T3/es active Active
- 2010-08-20 CA CA2771699A patent/CA2771699C/en active Active
- 2010-08-20 PT PT108106543T patent/PT2467140T/pt unknown
- 2010-08-20 JP JP2012525725A patent/JP5876827B2/ja active Active
- 2010-08-20 CN CN201080047795.1A patent/CN102770140B/zh active Active
- 2010-08-20 WO PCT/US2010/046142 patent/WO2011022633A2/en not_active Ceased
- 2010-08-20 EP EP10810654.3A patent/EP2467140B1/en not_active Revoked
- 2010-08-20 DK DK10810654.3T patent/DK2467140T3/en active
- 2010-08-20 MX MX2012002161A patent/MX367580B/es active IP Right Grant
- 2010-08-20 US US13/391,579 patent/US20120156200A1/en not_active Abandoned
- 2010-08-20 PL PL10810654T patent/PL2467140T3/pl unknown
- 2010-08-20 AU AU2010284092A patent/AU2010284092A1/en not_active Abandoned
- 2010-08-20 KR KR1020127007152A patent/KR101781658B1/ko not_active Expired - Fee Related
- 2010-08-20 RS RS20160681A patent/RS55074B1/sr unknown
- 2010-08-20 EA EA201270298A patent/EA027959B1/ru not_active IP Right Cessation
- 2010-08-20 HU HUE10810654A patent/HUE029098T2/en unknown
- 2010-08-20 LT LTEP10810654.3T patent/LT2467140T/lt unknown
- 2010-08-20 CA CA3080511A patent/CA3080511C/en active Active
- 2010-08-20 BR BR112012003653A patent/BR112012003653A2/pt not_active IP Right Cessation
-
2012
- 2012-02-15 ZA ZA2012/01110A patent/ZA201201110B/en unknown
- 2012-02-20 IL IL218230A patent/IL218230B/en active IP Right Grant
-
2014
- 2014-06-17 AU AU2014203270A patent/AU2014203270B2/en not_active Revoked
-
2015
- 2015-02-27 US US14/634,052 patent/US9539257B2/en active Active
-
2016
- 2016-09-01 CY CY20161100861T patent/CY1118486T1/el unknown
- 2016-09-01 SM SM201600296T patent/SMT201600296B/it unknown
- 2016-11-21 US US15/356,719 patent/US10004742B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wapner et al. | Expanding the scope of noninvasive prenatal testing: detection of fetal microdeletion syndromes | |
| Tassopoulou-Fishell et al. | Genetic variation in myosin 1H contributes to mandibular prognathism | |
| Padyukov et al. | A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis | |
| ME02492B (me) | Lapatanib za lečenje kancera | |
| Breton et al. | Prenatal tobacco smoke exposure is associated with childhood DNA CpG methylation | |
| Almén et al. | Genome-wide analysis reveals DNA methylation markers that vary with both age and obesity | |
| Medrano et al. | Role of TNFRSF1B polymorphisms in the response of Crohn’s disease patients to infliximab | |
| He et al. | Association between the HLA-B* 15: 02 allele and carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Han individuals of northeastern China | |
| Jobim et al. | Analysis of KIR gene frequencies and HLA class I genotypes in breast cancer and control group | |
| Cai et al. | Assessment of tuberous sclerosis complex associated with renal lesions by targeted next-generation sequencing in mainland China | |
| López-Aladid et al. | Detection of cytomegalovirus drug resistance mutations in solid organ transplant recipients with suspected resistance | |
| JP2013502433A5 (me) | ||
| Ahn et al. | Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma | |
| Sivaram et al. | Macrophage migration inhibitory factor, Toll-like receptor 4, and CD14 polymorphisms with altered expression levels in patients with ulcerative colitis | |
| Hayat et al. | Association of matrix metalloproteinase-9 polymorphism with severity of Guillain-Barré syndrome | |
| Han et al. | Potential contribution of the neurodegenerative disorders risk loci to cognitive performance in an elderly male gout population | |
| Søndergaard et al. | Genetic burden of MS risk variants distinguish patients from healthy individuals but are not associated with disease activity | |
| Lin et al. | Angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to osteoarthritis of the knee: a case-control study and meta-analysis | |
| RU2014123166A (ru) | Восприимчивость к ингибиторам ангиогенеза | |
| JP2013526863A5 (me) | ||
| Christiansen et al. | Use of whole genome sequencing in the Dutch Acute HCV in HIV study: focus on transmitted antiviral resistance | |
| Lismer et al. | Exposure of Greenlandic Inuit and South African VhaVenda men to the persistent DDT metabolite is associated with an altered sperm epigenome at regions implicated in paternal epigenetic transmission and developmental disease–a cross-sectional study | |
| Wu et al. | Study of the tetraspanin 18 association with schizophrenia in a Han Chinese population | |
| Saridi | Malignancy Risk and Safety Issues of Azathioprine in Patients with Inflammatory Bowel Disease: Clinical Experience from a Referral Center | |
| D'Amato et al. | WJGO |